Communiqué from the Annual General Meeting of Chordate Medical Holding AB (publ)

The Annual General Meeting of Chordate Medical Holding AB (publ) was held on May 15, 2024. The following decisions were made at the Annual General Meeting.

Income statements and balance sheets
The Annual General Meeting adopted the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet for the financial year 2023.

Dividend
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be distributed for the financial year 2023 and that the company’s result shall be carried forward in the new accounts.

Discharge from liability
The members of the Board of Directors and the CEO were discharged from liability for the administration of the company during the financial year 2023.

Election of members of the Board of Directors
The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, that the Board of Directors, for the period running up until the end of the next Annual General Meeting, shall be composed of five board members with no deputy board members.

The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, on the re-election of the board members Henrik Rammer, Tommy Hedberg, Caroline Lundgren Brandberg, Gunilla Lundmark and Otto Skolling for the period running up until the end of the next Annual General Meeting. Otto Skolling was elected Chairman of the Board of Directors for the period running up until the end of the next Annual General Meeting.

Election of auditor
The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, that one registered accounting firm shall be elected as auditor for the period running up until the end of the next Annual General Meeting.

The Annual General Meeting re-elected, in accordance with the nomination committee’s proposal, the auditing firm Öhrlings PricewaterhouseCoopers AB as auditor for the period running up until the end of the next Annual General Meeting. The Authorized Public Accountant, Henrik Boman, will be the responsible auditor.

Fees to the board of directors and the auditor
The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, that fees to the board of directors, for the period up until the end of the next annual general meeting, shall amount to a total of SEK 580,000 with the following distribution: SEK 180,000 to the chairman of the board of directors and SEK 100,000 to each of the other members of the board of directors who are not employed by the company.

The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, that the fee to the auditor, for the period up to the end of the next annual general meeting, shall be paid as incurred on approved accounts.

Guidelines for appointing the nomination committee
The Annual General Meeting resolved, in accordance with the nomination committee’s proposal, that the nomination committee shall consist of the four largest shareholders namely HAWOC Investment AB, Sifonen, Isak Brandberg AB with closely related persons, and Tommy Hedberg with closely related persons. The term of the nomination committee shall run until a new nomination committee has been appointed.

Amendment to the articles of association with respect to the share capital
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on an amendment to the articles of association in order to enable the reduction of the share capital. The amendment of the articles of association entail that the limits of share capital are changed from that the share capital shall not be less than SEK 55,000,000 and not more than SEK 220,000,000 to that the share capital shall not be less than SEK 9,000,000 and not more than SEK 36,000,000.

Reduction of the share capital
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on an reduction of the share capital. The share capital shall be reduced by SEK 48,808,786.50. The reduction of the share capital shall be carried out without withdrawal of shares, and the amount from the reduction shall be allocated to unrestricted equity. The reduction is implemented for the purpose of reducing the quota value of the shares from SEK 0.12 per share to SEK 0.02 per share. Following the reduction, the company's share capital will amount to SEK 9,761,757.30, divided into a total of 488,087,865 shares (before the issue of shares in accordance with the below and the consolidation of shares in accordance with the below).

Directed issue of shares (equalization issue)
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on an issue of shares, with deviation from the shareholders’ preferential rights, in order to achieve a number of shares in the company that is evenly divisible by five-hundred (500), in order to enable the consolidation of shares in accordance with the below and to contribute shares to the shareholders whose number of shares is not evenly divisible by five-hundred (500).

Through the share issue, the company’s share capital is increased by not more than SEK 40,472.70 through the issue of not more than 2,023,635 new shares, each with a quota value of SEK 0.02 (after the completion of the reduction set out above). The right to subscribe for the new shares shall vest with Vator Securities AB. The reasons for the deviation from the shareholders preferential rights is to ensure that the total number of shares in the company is evenly divisible by five-hundred (500) and that the relevant shares can be allotted to shareholders whose shareholding are not evenly divisible by five-hundred (500).

A subscription price of SEK 0.02 shall be paid for each new share. The subscription price corresponds to the shares’ quota value (after the completion of the reduction set out above). Subscription for shares shall be made not later than three (3) days following the general meeting’s resolution. Payment shall be made not later than five (5) days following the general meeting’s resolution. The board of directors shall have the right to extend the subscription period and the time for payment.

Amendment to the articles of association with respect to the number of shares
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on an amendment to the articles of association in order to enable the consolidation of shares. The amendment of the articles of association entail that the limits regarding the number of shares are changed from that the number of shares in the company shall not be less than 450,000,000 and not more than 1,800,000,000 to that the number of shares in the company shall not be less than 900,000 and not more than 3,600,000.

Consolidation of shares
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on a consolidation of the company’s shares, whereby the number of shares in the company is reduced by combining five-hundred (500) shares into one (1) share, in order to achieve a suitable number of shares in the company. The annual general meeting authorized the board of directors to determine the record date for the consolidation.

If a shareholder’s shareholding does not correspond to a full number of new shares, i.e., is not evenly divisible by five-hundred (500), such shareholder will receive as many shares as necessary free of charge (1-499) that their shareholding, after adding the shares provided, becomes evenly divisible by five-hundred (500), so-called rounding up.

Further information on the procedure for the consolidation will be announced in connection with the board of directors resolving on the record date.

Authorization for the board of directors to resolve on issuances
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, to authorize the board of directors, on one or more occasions, until the next annual general meeting, with or without preferential rights for the shareholders, to resolve upon issue of shares, convertibles and/or warrants. Such new issue resolutions may include provisions of payment in cash and/or payment by way of contribution of non-cash consideration or by set-off of a claim or that subscription shall be subject to other conditions. The terms and conditions for the issue shall be customary to market practice with the possibility to a customary issue discount and shares, warrants and/or convertibles may be issued up to a volume corresponding to in total not more than one-third (1/3) of the shares outstanding in the company at any given time.

Amendment of the articles of association
The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on an amendment of the articles of association in order to enable the board of directors to adopt a resolution that a general meeting shall be held digitally.

Chordate Presents Ozilia at Pharma Partnering EU Summit 2024

Chordate Medical's CEO, Anders Weilandt, will present the company and the migraine treatment Ozilia at Pharma Partnering EU Summit in Basel, Switzerland, on May 22–23. The congress gathers leading figures from around the world, primarily within the pharmaceutical industry, focusing on licensing, commercialization, investment, and other partnership opportunities.

"Unlike other investment conferences we participate in, this one is focused on the pharmaceutical industry, where we know there is substantial interest in innovations like Ozilia. The goal is to come away with a number of promising leads to follow up on," says Anders Weilandt.

Chordate's participation in the Pharma Partnering EU Summit is part of the company's efforts to increase awareness about the company and Ozilia in various industry and investor segments.

"The company's exit strategy is based on how the entire medtech industry has evolved in recent years – large players increasingly acquire smaller development companies that have demonstrated proof of concept and market potential, rather than developing innovative treatments themselves. This is especially true for the pharmaceutical industry."

Read more about the Pharma Partnering EU Summit 2024

Chordate will be granted a fourth patent in the USA

Chordate Medical Holding AB (Publ.) announces that the United States Patent and Trademark Office has issued a decision to grant Chordate's patent application US 17/942,912 from 2022.

The patent application relates to the treatment of headaches, focusing on protecting the company's product Ozilia Migraine. The granting of the application means that a fourth U.S. patent is added to a growing patent family focused on headache treatment, which the company has been building since 2011.

"One of the three cornerstones of our strategic efforts to build shareholder value is to fulfill our patent strategy. The intellectual property defense of our technology to support our ongoing business development is an essential part of what we consider core values in the company," says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical today holds 79 patents across 32 countries and 9 patent families, covering various aspects of the company’s treatment technologies. The patent families deal with various aspects of Chordate’s technology and are designed to provide the best possible protection for the inventions that is the basis for the company’s products.

Chordate presents Ozilia at LSX World Congress on April 29-30

Chordate Medical is participating in this year's LSX World Congress in London on April 29-30. LSX World Congress is a leading event in the global life science sector, connecting innovative new solutions and start-up companies with major corporations and investors.

"LSX brings together potential investors in biotech, medtech, and healthtech from around the world in one place. It's a very fitting forum for us to present Ozilia as the latest development in migraine treatment," says Anders Weilandt, CEO of Chordate.

This year's edition of LSX World Congress is the tenth in its series. The purpose of the event is to connect capital with innovative developments to help create tomorrow's health solutions that can benefit more people.

"We already have the scientific evidence in place and are beginning to show proof of concept in several of our focus markets. The next step in the company's strategy is to find a buyer for the company. At LSX World Congress and other similar events we participate in during the spring, we find precisely the right target audience for us."

Read more about LSX World Congress

Chordate presents Ozilia to national specialist associations from Germany, Switzerland, & Austria

Chordate Medical will exhibit at the Dreiländertagung Kopfschmerz congress in Switzerland from April 25th to 27th. The congress is jointly organized by specialist associations from Germany, Switzerland, and Austria.

"It's an excellent opportunity for us to introduce Ozilia and inform a large number of migraine and headache specialists from three significant European markets all at once," says Anders Weilant, CEO of Chordate.

The congress will bring together headache specialists and neurologists to discuss and present the latest developments in migraine treatment, with neuromodulation being one of the topics on the agenda.

"In addition to raising awareness of Ozilia among potential investors and buyers of the company, it's important that we continue to engage with the profession in various markets. Interest in neuromodulation as a treatment technique for migraine among specialists and neurologists is growing, and Ozilia is a unique and new treatment option that an increasing number is evaluating."

Learn more about the congress

Chordate presents at the Feminvest investor conference in Oslo

Chordate Medical's Caroline Lundgren Brandberg, non-executive Director and main owner, will participate in the Fearless investor conference hosted by Feminvest in Oslo on April 25th, where she will present Chordate Medical and Ozilia Migraine. Chordate's chairman, Henrik Rammer, will also be present in Oslo. Feminvest is the largest network for female investors and entrepreneurs in the Nordic region.

"Our participation at Feminvest aligns with our increasing focus on raising awareness about the company and Ozilia across various industry and investor segments. Feminvest has a strong network of investors focused specifically on femtech and life science, where Ozilia fits into both areas," says Caroline Lundgren Brandberg, non-executive Director of Chordate Medical.

Feminvest is an acceleration network for female ownership through education, as well as an investment venture. It is currently the largest hub for female investors and entrepreneurs in the Nordic region with almost 47,000 subscribers. Feminvest also operates a network of 300 female angel investors. For Chordate Medical, the investor event in Oslo on April 25 is one of several meeting points during the spring. On the same date, the company's CEO, Anders Weilandt, will be in Switzerland showcasing Ozilia at a joint congress for specialist associations from Switzerland, Germany, and Austria.

"As Ozilia gains increasing acceptance and success in our target markets, it is natural for us to expand efforts to raise awareness for Ozilia among potential investors and buyers of the company," says Anders Weilandt, CEO of Chordate.

Caroline Lundgren Brandberg, MSc. Eng. Physics, eMBA, has been a board member of Chordate Medical since 2021. Caroline is the Global Sales Director at climate tech company Deedster and has previously worked internationally for Ericsson in various leadership roles with a focus on sales and marketing. She also holds several board and advisory board positions, including at Stockholm University.

Read more about Feminvest Fearless

Chordate Medical Holding AB (publ) Appoints Lago Kapital as Liquidity Provider

Chordate Medical Holding AB (publ) ("Chordate") has entered into an agreement for liquidity provision with Lago Kapital ("Lago").

According to the agreement, Lago will provide trading posts in Chordate's stock on both the buy and sell sides in accordance with and within the framework of Nasdaq Stockholm's rules for liquidity provision. The purpose of liquidity provision is to improve liquidity and reduce volatility. Lago's assignment commences on April 19th, 2024.

Notice to the Annual General Meeting in Chordate Medical Holding AB (publ)

The shareholders in Chordate Medical Holding AB (publ), 556962-6319, are hereby given notice of the annual general meeting to be held on Wednesday 15 May 2024, at 15:00 at the company’s premises, Regus, Kistagången 20 B in Kista, Sweden.

Registration and notification

Shareholders who wish to participate at the general meeting must

  • be recorded in the share register kept by Euroclear Sweden AB on Monday 6 May 2024, and
  • give notice of their intention to participate at the general meeting no later than Wednesday 8 May 2024 by post to Chordate Medical Holding AB (publ), c/o Regus, Kistagången 20 B, 164 40 Kista (please mark the envelope ”AGM Chordate”), by telephone to 08-400 115 46 or by e-mail to niklas.lindecrantz@chordate.com.

For shareholders who have their shares registered through a bank or other nominee, the following applies in order to be entitled to participate in the general meeting. In addition to giving notice of participation to the general meeting, such shareholder must re-register its shares in its own name so that the shareholder is registered in the share register kept by Euroclear Sweden AB as of the record date on 6 May 2024. Such registration may be temporary (so-called voting rights registration). Shareholders who wish to register their shares in their own names must, in accordance with the respective nominee´s routines, request that the nominee makes such registration. Voting rights registration that have been requested by the shareholder at such time that the registration has been completed by the nominee no later than on 8 May 2024, will be taken into account in the preparation of the share register.

Power of attorney

If a shareholder wishes to attend the general meeting by proxy, a written and dated power of attorney signed by the shareholder in original copy must be sent by post to Chordate Medical Holding AB (publ), c/o Regus, Kistagången 20 B, 164 40 Kista. A proxy form is available on the company's website www.chordate.com. If the shareholder is a legal person, a certificate of registration or other authorization document must be attached to the form.

Agenda for the general meeting

1. Opening of the general meeting
2. Election of chairman at the general meeting
3. Preparation and approval of the voting list
4. Election of one or two persons who shall approve the minutes of the general meeting
5. Determination of whether the meeting has been duly convened
6. Approval of the agenda
7. Presentation of the annual report and the auditor’s report as well as the consolidated financial statement and the auditor’s report for the group as well as presentation by the chairman of the board of directors and by the CEO
8. Resolution on
a. the adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet
b. the dispositions in respect of the company’s profit and loss pursuant to the adopted balance sheet
c. discharge from liability of the directors and the CEO
9. Determination of the number of directors, deputy directors, auditors and deputy auditors
10. Determination of the fees to the board of directors and the auditor
11. Election of the board of directors and auditors
12. Resolution on guidelines for appointing the nomination committee
13. Proposal on resolution on
a. amendment to the articles of association with respect to the share capital
b. reduction of the share capital
c. directed issue of shares (equalization issue)
d. amendment to the articles of association with respect to the number of shares
e. consolidation of shares
14. Proposal on an authorization for the board of directors to resolve on issuances
15. Proposal on resolution to amend the articles of association
16. Closing of the meeting

Proposed resolutions

Item 2 – Election of chairman at the general meeting

The nomination committee proposes that attorney Niklas Larsson, CMS Wistrand, or the person proposed by the board of directors if he has an impediment to attend, is elected chairman of the annual general meeting and that attorney Sebastian Petersen, CMS Wistrand, or the person proposed by the board of directors if he has an impediment to attend, is elected keeper of the minutes of the annual general meeting.

Item 8 b – Resolution on the dispositions in respect of the company’s profit and loss pursuant to the adopted balance sheet

The board of directors proposes that no dividend shall be distributed for the financial year 2023 and that the company’s result shall be carried forward in the new accounts.

Item 9 – Determination of the number of directors, deputy directors, auditors and deputy auditors

The nomination committee proposes that the board of directors, for the period up to the end of the next annual general meeting, shall be composed of five directors with no deputy directors and that one registered accounting firm is elected as auditor.

Item 10 – Determination of the fees to the board of directors and the auditor

The nomination committee proposes that fees to the board of directors, for the period up to until the end of the next annual general meeting, shall amount to a total of SEK 580,000 with the following distribution: SEK 180,000 to the chairman of the board of directors and SEK 100,000 to each of the other members of the board of directors who are not employed by the company.

The nomination committee proposes that the fee to the auditor, for the period up to the end of the next annual general meeting, shall be paid as incurred on approved accounts.

Item 11 – Election of the board of directors and auditors

The nomination committee proposes re-election of the members of the board of directors Henrik Rammer, Tommy Hedberg, Caroline Lundgren Brandberg, Gunilla Lundmark and Otto Skolling for the period up to until the end of the next annual general meeting.

Furthermore, the nomination committee proposes the election of Otto Skolling as a new chairman of the board of directors for the period up to the end of the next annual general meeting.

Furthermore, the nomination committee proposes re-election of Öhrlings PricewaterhouseCoopers AB as auditor for the period up to the end of the next annual general meeting. Öhrlings PricewaterhouseCoopers AB has announced that the authorized public accountant, Henrik Boman, will be the responsible auditor.

Item 12 – Guidelines for appointing the nomination committee

It is proposed that the annual general meeting resolves that the nomination committee should continue to consist of the four largest shareholders at the time of the notice, namely HAWOC Investment AB, Sifonen, Isak Brandberg AB with closely related persons, and Tommy Hedberg with closely related persons. In the event that a member of the nomination committee resigns, is prevented from performing his/her duties, or if the owner who appointed the member offers their place, the remaining members of the nomination committee shall, if they so decide, among the company's shareholders, appoint a suitable replacement to the nomination committee for the remaining term. In the event that someone acquires shares in the company to such an extent that they become one of the four largest owners of the company, the nomination committee may decide to invite a representative for this shareholder as an additional member of the nomination committee.

The term of the nomination committee shall run until a new nomination committee has been appointed. The company is responsible for costs associated with the performance of the nomination committee's duties. Members of the nomination committee do not receive any remuneration from the company.

The nomination committee's duties shall include evaluating the composition and work of the board of directors and submitting proposals to the annual meeting regarding:

  • Chairman of the annual general meeting
  • The number and nominations of members of the board of directors to be elected by general meeting
  • The chairman of the board of directors
  • Remuneration to board members not employed by the company
  • If applicable, nomination of auditor and auditor’s fees
  • If applicable, guidelines for the appointment of members of the nomination committee and the duties of the nomination committee.

Item 13 – Proposal regarding resolution on a) amendment to the articles of association with respect to the share capital, b) reduction of the share capital c) directed issue of shares (equalization issue), d) amendment to the articles of association with respect to the number of shares, and e) consolidation of shares.

The board of directors proposes that the general meeting resolves on a) amendment to the articles of association with respect to the share capital, b) reduction of the share capital c) directed issue of shares (equalization issue), d) amendment to the articles of association with respect to the number of shares, and e) consolidation of shares. The proposals should be considered as a single proposal and therefore be adopted by the shareholders' meeting as one and the same resolution.

Item 13 a) – Amendment to the articles of association with respect to the share capital (step 1)

In order to enable the reduction of the share capital as set out in item b) below, the board of directors proposes that the general meeting resolves on an amendment to the articles of association with respect to the limits of share capital (4 §) from ”The share capital shall not be less than SEK 55,000,000 and not more than SEK 220,000,000” to ”The share capital shall not be less than SEK 9,000,000 and not more than SEK 36,000,000”.

Item 13 b) – Reduction of the share capital

The board of directors proposes that the general meeting resolves on an reduction of the share capital on the following terms and conditions.

The capital shall be reduced by SEK 48,808,786.50. The reduction of the share capital shall be carried out without withdrawal of shares, and the amount from the reduction shall be allocated to unrestricted equity. The reduction is implemented for the purpose of reducing the quota value of the shares from SEK 0.12 per share to SEK 0.02 per share. Following the reduction, the company's share capital will amount to SEK 9,761,757.30, divided into a total of 488,087,865 shares (before the proposed issue of shares according to item c) below and the proposed consolidation of shares according to item e) below).

The reduction of the share capital requires an amendment to the articles of association.

Item 13 c) – Directed issue of shares (equalization issue)

In order to achieve a number of shares in the company that is evenly divisible by fivehundred (500), which enables the consolidation of shares in accordance with item e) below and to contribute shares to the shareholders whose number of shares is not evenly divisible by five-hundred (500), the board of directors proposes that the general meeting resolves on an issue of shares with deviation from the shareholders’ preferential rights. The resolution shall otherwise be governed by the following terms and conditions.

Through the share issue, the company’s share capital shall increased by not more than SEK 40,472.70 through a new issue of not more than 2,023,635 new shares, each with a quota value of SEK 0.02 (after the completion of the reduction as set out in b) above).

The right to subscribe for the new shares shall, with deviation from the shareholders’ preferential rights, vest with Vator Securities AB. The reasons for the deviation from the shareholders preferential rights is to ensure that the total number of shares in the company is evenly divisible by five-hundred (500) and so that the relevant shares are allotted to shareholders whose shareholding are not evenly divisible by five-hundred (500).

A subscription price of SEK 0.02 shall be paid for each new share. The subscription price corresponds to the shares’ quota value (after the completion of the reduction as set out in b) above).

Subscription for shares shall be made on a subscription list provided by the company not later than three (3) days following the general meeting’s resolution. Payment shall be made to an account designated by the company not later than five (5) days following the general meeting’s resolution. The board of directors shall have the right to extend the subscription period and the time for payment.

The new shares shall entitle to dividends for the first time on the record date for dividend occurring after the shares have been registered with the Swedish Companies Registration Office and entered into the share register kept by Euroclear Sweden AB.

Item 13 d) – Amendment to the articles of association with respect to the number of shares (step 2)

In order to enable the consolidation of shares as set out in item e) below, the board of directors proposes that the general meeting resolves on an amendment to the articles of association whereby the limits regarding the number of shares (4 §) are changed from ”The number of shares in the company shall not be less than 450,000,000 and not more than 1,800,000,000" to "The number of shares in the company shall not be less than 900,000 and not more than 3,600,000".

Item 13 e) – Consolidation of shares

In order to achieve a suitable number of shares in the company, the board of directors proposes that the general meeting resolves upon a consolidation of the company’s shares in relation 1:500 (after the completion of the equalization issue as set out in c) above), whereby the number of shares in the company is reduced by combining five-hundred (500) shares into one (1) share. The board of directors shall be authorized to determine the record date for the consolidation (to occur after the resolution has been registered with the Swedish Companies Registration Office) and to take all other measures required for implementing the consolidation.

If a shareholder’s shareholding does not correspond to a full number of new shares, i.e., is not evenly divisible by five-hundred (500), such shareholder will receive as many shares as necessary free of charge (1-499) that their shareholding, after adding the shares provided, becomes evenly divisible by five-hundred (500), so-called rounding up.

Further information on the procedure for the consolidation will be announced in connection with the board of directors resolving on the record date.

General aspects regarding the proposal

The board of directors, or a person appointed by the board of directors, shall be authorized to make any minor adjustments required to register the resolutions with the Swedish Companies Registration Office, Euroclear Sweden AB or due to other formal requirements.

A valid resolution requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as of all shares represented at the meeting.

The resolution under item c) above is conditional upon that the resolutions under items a) – b) above are registered with the Swedish Companies Registration Office, and the resolutions under items d) – e) above are conditional upon that the resolution under item c) above is registered with the Swedish Companies Registration Office.

Item 14 – Proposal regarding authorization for the board of directors to resolve on issuances

The board of directors proposes that the general meeting authorizes the board of directors, on one or more occasions, until the next annual general meeting, with or without preferential rights for the shareholders, to resolve upon issue of shares, convertibles and/or warrants. Such new issue resolutions may include provisions of payment in cash and/or payment by way of contribution of non-cash consideration or by set-off of a claim or that subscription shall be subject to other conditions. The terms and conditions for the issue shall be customary to market practice with the possibility to a customary issue discount and shares, warrants and/or convertibles may be issued up to a volume corresponding to in total not more than one-third (1/3) of the shares outstanding in the company at any given time.

The board of directors, or a person appointed by the board of directors, shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.

A valid resolution requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as of all shares represented at the meeting.

Item 15 – Proposal on resolution to amend the articles of association

In order to enable the board of directors to adopt a resolution that a general meeting shall be held digitally, the board of directors proposes that the general meeting resolves that the current § 8 become § 9, that the current § 9 become § 10 and that the current § 10 become § 11 and that a new § 8 “General Meeting” is introduced as follows: “The board of directors may adopt a resolution that a general meeting shall be held digitally”.

The board of directors, or a person appointed by the board of directors, shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.

A valid resolution requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as of all shares represented at the meeting.

Miscellaneous

The board of directors and the CEO shall, if any shareholder so requests and the board of directors considers that it can be done without material harm to the company, provide information on matters that may affect the assessment of an item on the agenda and conditions that may affect the assessment of the company’s financial situation.

Copies of the annual financial report and the auditor’s report will be available at the company’s website, www.chordate.com, no later than two weeks prior to the general meeting. Copies of such documentation will be sent to shareholders who so requests and provides its address.

The total number of shares and votes of the company as per the date of this notice amounts to 488,087,865.

For the processing of personal data, please refer to the privacy policy available at the following link: https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

_____________________
Chordate Medical Holding AB (publ)
the board of directors

Chordate Medical Holding AB publishes annual report for 2023

Chordate Medical Holding AB (Publ) has today published its annual report for 2023. The annual report is available on Chordate's website www.chordate.com and is attached to this press release.

Chordate Medical’s CEO Anders Weilandt interviewed about year-end report by Finwire

Yesterday, March 25th, Chordate's CEO Anders Weilandt presented the company's financial report for 2023 on Finwire TV. He also answered questions from viewers, discussing, among other things, the company's efforts to raise awareness about the migraine treatment Ozilia among established investors in the life science sector:

"We have made 4-5 quite substantial efforts during the autumn at international migraine congresses. It has generated a substantial number of leads with prominent interest from various countries. When it comes to our target markets, we work on that directly from Stockholm first, and make sure to establish contact. Then we work together with our market access consultants in each country and/or distributors to continue the process. This has been ongoing throughout the autumn and is still ongoing now, and more results from this will be coming very soon."

Anders also specifically discussed the interest in Ozilia at Swiss Nordic Bio, and the plan going forward:

"We received very good feedback and had many interesting meetings. We will continue to devote a lot of time to this type of partner and investor meetings in an organized manner. We had a presence at another congress in Amsterdam a few weeks earlier, and there are a few more coming up during the spring. Marketing ourselves in that environment is part of the work to fulfill the strategic plan."

Watch the full interview